BioSpace News Archive

The board of directors of Abbott declared a quarterly common dividend of 47 cents per share.

Todos Medical, Ltd. announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 45 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in February 2021 and experienced symptoms of Long COVID.

Abivax SA held its ordinary annual and extraordinary general meeting of shareholders on June 9, 2022, which was chaired by Prof. Hartmut Ehrlich, M.D., CEO of Abivax, in the absence of the Chairman of the Board of directors.

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers.

Disc Medicine, today presented the results from its phase 1 clinical study of DISC-0974, a first-in-class, monoclonal antibody designed to suppress hepcidin production by inhibiting hemojuvelin (HJV), at the European Hematology Association (EHA) Congress being held in Vienna, Austria.

bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell (RBC) transfusions.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs’ 43rd Annual Global Healthcare Conference.

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43rd Annual Healthcare Conference at 1:40 p.m. ET on Wednesday, June 15, 2022.

NLS Pharmaceutics Ltd. announces that it has received a written notice from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.

Galderma announced at the Vegas Cosmetic Surgery & Aesthetic Dermatology meeting, topline results from two phase III clinical studies demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months.